By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Precision
BioSciences, Inc. et al. v. Cellectis SA et al.
5:12-cv-00719;
filed November 5, 2012 in the Eastern District of North Carolina

• Plaintiffs: 
Precision BioSciences, Inc.; Duke University
• Defendants: 
Cellectis SA; Cellectis bioresearch; Cellectis bioresearch Inc.

Infringement
of U.S. Patent No. 8,304,222 ("Methods of Cleaving DNA with
Rationally-Designed Meganucleases," issued November 6, 2012) based on
Cellectis' manufacture, use, and sale of certain products, including the
CLS4617 meganuclease targeting the human CCR5 gene and meganucleases targeting
the human RAG1 gene.  View the complaint here.

Astrazeneca
Pharmaceuticals LP et al. v. Lupin Ltd. et al.
3:12-cv-06888;
filed November 5, 2012 in the District Court of New Jersey

• Plaintiffs: 
Astrazeneca Pharmaceuticals LP; Astrazeneca UK Ltd.;
• Defendants: 
Lupin Ltd.; Lupin Pharmaceuticals, Inc.

Infringement
of U.S. Patent No. 5,948,437 ("Pharmaceutical Compositions Using
Thiazepine," issued September 7, 1999) following a Paragraph IV certification
as part of Lupin's filing of an ANDA to manufacture a generic version of
AstraZeneca's Seroquel® XR (quetiapine fumarate, used to treat schizophrenia
and bipolar disorder).  View the
complaint here.

Genetic
Technologies Ltd. v. PreventionGenetics LLC
3:12-cv-00792;
filed November 2, 2012 in the Western District of Wisconsin

Infringement
of U.S. Patent No. 5,612,179 ("Intron Sequence Analysis Method for
Detection of Adjacent Locus Alleles as Haplotypes," issued March 18, 1997)
based on RGI's manufacture, use, sale, and offer for sale of clinical DNA
testing services.  View the complaint here.

Acura
Pharmaceuticals, Inc. v. Sandoz, Inc.
3:12-cv-06784;
filed November 1, 2012 in the District Court of New Jersey

Infringement
of U.S. Patent No. 7,510,726 ("Methods and Compositions for Deterring
Abuse of Opioid Containing Dosage Forms," issued March 31, 2009) following
a Paragraph IV certification as part of Sandoz's filing of an ANDA to
manufacture a generic version of Oxecta® (oxycodone hydrochloride, used for the
management of acute and chronic moderate to severe pain where the use of an
opioid analgesic is appropriate, marketed by Pfizer).  View the complaint here.

Purdue
Pharmaceutical Products L.P. et al. v. Par Pharmaceutical, Inc.
2:12-cv-06738;
filed October 25, 2012 in the District Court of New Jersey

• Plaintiffs:  Purdue
Pharmaceutical Products L.P.; Purdue Pharma L.P.; Transcept Pharmaceuticals,
Inc.
• Defendant:  Par
Pharmaceutical, Inc.

Purdue
Pharmaceutical Products L.P. et al. v. Par Formulations Private Ltd.
2:12-cv-06741;
filed October 25, 2012 in the District Court of New Jersey

• Plaintiffs: 
Purdue Pharmaceutical Products L.P.; Purdue Pharma L.P.; Transcept
Pharmaceuticals, Inc.
• Defendant: 
Par Formulations Private Ltd.

The
complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 8,242,131 ("Methods
of Treating Middle-of-the-Night Insomnia," issued August 14, 2012) and
8,252,809 ("Compositions for Treating Insomnia," issued August 28,
2012) following a Paragraph IV certification as part of Par's filing of an ANDA
to manufacture a generic version of Purdue's Intermezzo® (sublingual zolpidem
tartrate, used to treat insomnia when middle-of-the-night awakening is followed
by difficulty returning to sleep).  View
the Par Pharmaceutical complaint here.

Mallinckrodt
Inc. et al. v. Watson Laboratories, Inc.-Florida. et al.
2:12-cv-06744;
filed October 25, 2012 in the District Court of New Jersey

• Plaintiffs: 
Mallinckrodt Inc.; Mallinckrodt LLC
• Defendants: 
Watson Laboratories, Inc.-Florida; Watson Pharma, Inc.; Watson
Pharmaceuticals, Inc.

Infringement
of U.S. Patent No. 5,914,131 ("Hydromorphone Therapy," issued June
22, 1999) following a Paragraph IV certification as part of Watson's filing of
an ANDA to manufacture a generic version of Mallinckrodt's Exalgo®
(hydromorphone hydrochloride, used for the management of moderate to severe
pain in opioid tolerant patients requiring continuous, around-the-clock opioid
analgesia for an extended period of time). 
View the complaint here.

Gilead
Sciences, Inc. v. Lupin Ltd.
1:12-cv-07910;
filed October 24, 2012 in the Southern District of New York

Infringement
of U.S. Patent Nos. 5,922,695 ("Antiviral Phosphonomethoxy Nucleotide
Analogs Having Increased Oral Bioavailability, issued July 13, 1999), 5,935,946
("Nucleotide Analog Composition and Synthesis Method," issued August
10, 1999), 5,977,089 ("Antiviral Phosphonomethoxy Nucleotide Analogs
Having Increased Oral Bioavailability, issued November 2, 1999), and 6,043,230
(same title, issued March 28, 2000), following a Paragraph IV certification as
part of Lupin's filing of an ANDA to manufacture generic versions of Gilead's
Viread® (tenofovir disoproxil fumarate, used for the treatment of HIV-1
infection).  View the complaint here.